The largest database of trusted experimental protocols

Allegra

Allegra is a third-generation antihistamine medication used to treat symptoms of allergic rhinitis, such as sneezing, itchy and watery eyes, and nasal congestion.
It works by blocking the action of histamine, a chemical released by the body during an allergic reaction.
Allegra is available in both prescription and over-the-counter formulations, and is generally well-tolerated with few side effects.
It is an effective treatment option for managing seasonal and year-round allergies, helping to provide relief and improved quality of life for those suffering from allergic symptoms.
Experiance the power of AI-driven optimization today.

Most cited protocols related to «Allegra»

Forty-two male participants took part in this experiment (aged 18-31, mean age 23.1 years). The study was approved by the local Research Ethics Committee. Functional images were acquired on a 3T Siemens Allegra scanner using a gradient-echo EPI pulse sequence. Imaging data were analyzed with SPM5 (www.fil.ion.ucl.ac.uk/spm/), including standard preprocessing procedures (spatial realignment, correction for differences in slice acquisition time, spatial normalization and smoothing) and modelling the data by a set of general linear models. During the virtual reality task, participants were presented with a first-person perspective of a grassy plane surrounded by a circular cliff. Participants moved the viewpoint by using their right hand to operate keys to move forward and turn left or right. Throughout the experiment, participants collected and replaced everyday objects within the arena. See methods and ref.11 (link) for details.
Publication 2010
Allegra ECHO protocol Ethics Committees, Research Males Poaceae Pulse Rate
Subjects used in this paper were part of a large study of early brain development in normal children [18] (link). The experimental protocols were approved by the institutional review board of the University of North Carolina (UNC) School of Medicine. The parents were recruited during the second trimester of pregnancy from the UNC hospitals and written informed consent forms were obtained from all the parents. The presence of abnormalities on fetal ultrasound, or major medical or psychotic illness in the mother, was taken as exclusion criteria. The infants were free of congenital anomalies, metabolic disease, and focal lesions. None of the subjects was sedated for MRI. Before the subjects were imaged, they were fed, swaddled, and fitted with ear protection.
Images were acquired on a Siemens head-only 3T scanner (Allegra, Siemens Medical System, Erlangen, Germany) with a circular polarized head coil. For T1-weighted images, 160 sagittal slices were obtained by using the three-dimensional magnetization-prepared rapid gradient echo (MPRAGE) sequence: TR = 1900 ms, TE = 4.38 ms, inversion time = 1100 ms, Flip Angle = 7°, and resolution = 1×1×1 mm3. For T2-weighted images, 70 transverse slices were acquired with turbo spin-echo (TSE) sequences: TR = 7380 ms, TE = 119 ms, Flip Angle = 150°, and resolution = 1.25×1.25×1.95 mm3. Data were collected longitudinally at 3 age groups: neonates, 1-year-olds, and 2-year-olds. Data with motion artifacts was discarded and a rescan was made when possible. Finally, complete 0–1–2 data of 95 normal infants was acquired. The demographic information was summarized in Table 2. Gestational ages were between 38.7 and 46.4 weeks at the first dates of examination. The variation of age at MRI for each scan is relatively small and the population can be divided in age groups concentrated around 0, 1, and 2 years of age.
Full text: Click here
Publication 2011
Age Groups Allegra Brain Child Congenital Abnormality ECHO protocol Ethics Committees, Research Fetal Ultrasonography Gestational Age Head Infant Infant, Newborn Inversion, Chromosome Magnetic Resonance Imaging Mental Disorders Metabolic Diseases Mothers MRI Scans Parent Pharmaceutical Preparations
CCM was harvested from SK-MES-1 cells and centrifuged using a Beckman Coulter Allegra® X-15R centrifuge at 300 g at 4°C for 10 minutes to remove detached cells. Supernatant was collected and filtered through 0.22 µm filters (Merck Millipore) to remove contaminating apoptotic bodies, microvesicles and cell debris. Clarified CCM was then centrifuged in a Beckman Coulter Optima™ L-80XP Ultracentrifuge at 100,000 gavg at 4°C for 90 minutes with a Type 50.2 Ti rotor (k-factor: 157.7) to pellet exosomes. The supernatant was carefully removed, and crude exosome-containing pellets were resuspended in 1 mL of ice-cold PBS and pooled. A second round of ultracentrifugation [100,000 gavg at 4°C for 90 minutes with a Type 50.2 Ti rotor (k-factor: 157.7)] was carried out, and the resulting exosome pellet resuspended in 500 µL of PBS (Supplementary Fig. 1).
Publication 2015
A 300 Allegra Apoptotic Bodies Cell-Derived Microparticles Cells Common Cold Exosomes Pellets, Drug Ultracentrifugation

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Allegra Brain Congenital Abnormality Cranium ECHO protocol fMRI Head Healthy Volunteers Pulse Rate Task Performance

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Allegra Fixation, Ocular fMRI Healthy Volunteers

Most recents protocols related to «Allegra»

All animal sampling and activities were performed in accordance with guidelines of the animal ethics committee of Vietnam National University of Agriculture. Blood was collected via right jugular vein venipuncture using a 20 gauge or smaller needle and syringe, with needle size adjusted per pig age. The 8–10 mL of blood collected was placed into a glass vial sans anticoagulant. The blood was allowed to clot at room temperature. Clotted blood was transferred to the laboratory under refrigerated conditions by placing the vials on ice gel packs in a transport container for serum extraction at the laboratory. Clotted blood was centrifuged for 10 min at 1,000 × g (Allegra™64R Centrifuge, Beckman Coulter), the sera were separated and aliquoted into 2 mL cryogenic vials, then stored at −80°C until further use.
Pig OF samples were collected using dry cotton swabs (prepared on 25 cm wooden stick). The cotton swab was used to rub inside the oral cavity, tonsils and pharynx of pigs 5–6 times so that the fluid was absorbed. Afterwards, the cotton swabs were transferred into a tube with 1.5 mL of phosphate-buffered saline (PBS—Tablets, USA) pH 7.4 and transported to the lab in an ice box. In the lab, the wooden stick was removed, and the cotton tip submerged in PBS was transferred into a zip bag. The fluid was collected by compressing the cotton swab in the bag. Aliquots of OF were placed into 2 mL cryogenic vials and stored at −80°C until tested.
Full text: Click here
Publication 2023
Allegra Animal Ethics Committees Animals Anticoagulants BLOOD Gossypium Jugular Vein Needles Oral Cavity Palatine Tonsil Pharynx Phlebotomy Phosphates Pigs Saline Solution Serum Syringes
Patients and HS-MRI underwent MRI examination at 3T (Magnetom Allegra, Siemens, Erlangen, Germany) that included the following acquisitions: (1) dual-echo turbo spin echo [TSE] (TR = 6190 ms, TE = 12/109 ms); (2) fast-FLAIR (TR = 8170 ms, 204TE = 96 ms, TI = 2100 ms); and (3) 3D modified driven equilibrium Fourier transform (MDEFT) scans (TR = 1338 ms, TE = 2.4 ms, matrix = 256 × 224 × 176, in-plane FOV = 250 × 250 mm2, slice thickness = 1 mm) to perform voxel-based morphometry on cerebellar gray matter (GM) maps. To characterize the brain anatomy and determine the presence of macroscopic structural abnormalities, TSE scans of patients were visually inspected by an expert neuroradiologist. For HS-MRI, conventional MRI scans were reviewed to ensure the absence of any macroscopic brain abnormality.
Full text: Click here
Publication 2023
Allegra Brain Cerebellar Gray Matter Congenital Abnormality ECHO protocol Microtubule-Associated Proteins MRI Scans Patients Radionuclide Imaging
Subjects avoided ingestion of the same substances outlined above for patients with coeliac disease for at least 48 hours before and during study days. They had a 10-hour overnight fast before testing. All studies had a randomised crossover design with fexofenadine 120 mg (Allegra, Hoechst Marion Roussel Inc, Laval, Quebec, Canada) consumed with 300 mL water or grapefruit juice. Plasma samples were obtained at the same specified times as those for the coeliac study. A standardised lunch was provided 4 hours after drug dosing (noon) that consisted of a sandwich, ginger ale and ice cream sandwich. The interval between study days was 1 week.
Publication 2023
Allegra Celiac Disease fexofenadine ginger extract Grapefruit Ice Cream Patients Pharmaceutical Preparations Plasma
Patients completed the fexofenadine pharmacokinetic study within 3 weeks of their endoscopy. They avoided consumption of any substance(s) which might have an impact on fexofenadine bioavailability, including grapefruit, orange and apple juices and fruits, tobacco, alcoholic drinks, medications (prescription and over-the-counter) and natural health products, for at least 48 hours before and during this study. All medications taken were documented before entry into the study. No patients were receiving a medication that was either an inhibitor or inducer of OATPs or P-glycoprotein. Testing was preceded by a 10-hour overnight fast. Fexofenadine 120 mg (Allegra, Hoechst Marion Roussel Inc, Laval, Quebec, Canada) was consumed with 300 mL water. Plasma samples were obtained at specified times (0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0 hours) relative to dosing for quantitation of fexofenadine concentrations. A gluten-free standardised lunch was provided 4 hours after drug dosing (noon).
Publication 2023
Alcoholic Beverages Allegra Citrus paradisi Drugs, Non-Prescription Endoscopy, Gastrointestinal fexofenadine Fruit Gluten-Free Diet Natural Products Organic Anion Transport Polypeptides P-Glycoprotein Patients Pharmaceutical Preparations Plasma Tobacco Products
At the end of each experimental period, microbial pellets from each fermenter vessel were harvested [38 (link)]. Briefly, total fermenter contents were blended for 1 min and filtered through 4 layers of cheesecloth with 200 mL of saline solution (0.9% NaCl). To remove the remaining feed particles, the filtrate was centrifuged (Allegra X-15R Centrifuge, Beckman Coulter Life Sciences, Indianapolis, IN, USA) at 1000× g for 10 min at 4 °C. The supernatant was collected and centrifuged (Sorvall RC-5B Refrigerated Superspeed Centrifuge, DuPont Instruments) at 11,250× g for 20 min at 4 °C for isolation of the microbial pellet. The microbial pellet was resuspended in 200 mL of McDougall’s solution for pellet purification and centrifuged at 16,250× g for 20 min at 4 °C. The final microbial pellet was resuspended in distilled water and transferred to a new container and kept at −20 °C until further analysis. The microbial pellet was freeze-dried for DM determination and analyzed for ash, total N, and 15N abundance.
We used 15N as a marker for microbial protein synthesis, and it was analyzed on artificial saliva, background digesta (before 15N-enriched saliva was used), digesta, and bacteria samples according to the following procedure. Freeze-dried samples were processed in 2 mL microcentrifuge tubes using 2.0 mm zirconia beads and homogenized (Precellys 24, Bertin, Rockville, MD, USA) at 5500× g for 10 s. Samples were weighed in tin capsules using a microscale (Excellence Plus XP Micro Balance Mettler-Toledo GmbH, Laboratory & Weighing Technologies, Columbus, OH, USA), and 35 µL of K2CO3 solution (10 g/L) were added to alkalinize the samples; the suspension was dried overnight in a forced-air oven at 40 °C to volatilize ammonia [39 (link)]. Analysis of 15N was performed with a mass spectrometer (IsoPrime 100, IsoPrime, Naperville, IL, USA), and the results were obtained as the fractional abundance of isotopic fractions (15N/14N). The equations used for the calculation of ruminal N metabolism are described below:
The percent excess of 15N of NAN (non-NH3-N) effluent was obtained by subtracting % atom 15N in the background from the % atom excess of 15N of NAN effluent [40 (link)].


Flows of NH3-N, NAN, and N metabolism were determined [41 (link)].

Microbial efficiency was determined as follows [40 (link)].

Efficiency of N used was determined as follows [41 (link)].

Full text: Click here
Publication 2023
Allegra Ammonia Bacteria Blood Vessel Capsule Fermentors Freezing isolation Isotopes Metabolism Normal Saline Pellets, Drug potassium carbonate Protein Biosynthesis Rumen Saline Solution Saliva Saliva, Artificial zirconium oxide

Top products related to «Allegra»

Sourced in United States, Germany, United Kingdom, France
The Allegra X-15R is a high-performance benchtop centrifuge designed for a wide range of laboratory applications. It offers a maximum speed of 15,000 rpm and a maximum relative centrifugal force (RCF) of 21,380 × g, making it suitable for numerous sample processing tasks. The centrifuge features a compact and ergonomic design, with a user-friendly control panel and a variety of rotor options to accommodate different sample volumes and tube sizes.
Sourced in Germany
The Magnetom Allegra is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging for diagnostic and research applications. The Magnetom Allegra features a powerful magnetic field and advanced technology to capture detailed images of the human body.
Sourced in Germany, United States
The Allegra scanner is a laboratory equipment product from Siemens. It is a magnetic resonance imaging (MRI) system designed for research applications. The Allegra scanner provides high-quality imaging capabilities for use in various research settings.
Sourced in United States, Ireland
The Allegra 64R is a high-performance refrigerated centrifuge designed for a wide range of laboratory applications. It offers a maximum speed of 20,000 RPM and a maximum RCF of 48,400 x g, providing efficient separation of samples. The Allegra 64R is equipped with a rotor capacity of up to 6 liters and can accommodate a variety of sample tubes and microplates. The centrifuge features a temperature range of -20°C to 40°C and maintains sample integrity through precise temperature control.
Sourced in United States
The Allegra X-15R Centrifuge is a high-performance laboratory centrifuge designed for a wide range of applications. It offers a maximum speed of 15,000 rpm and a maximum RCF of 21,380 x g. The centrifuge is equipped with a brushless motor and an intuitive control panel for easy operation.
Sourced in United States, Germany
The Allegra X-22R is a high-performance refrigerated benchtop centrifuge designed for a wide range of general laboratory applications. It features a maximum speed of 22,000 rpm and a maximum relative centrifugal force (RCF) of 53,800 x g. The Allegra X-22R is capable of accommodating a variety of rotor options to meet diverse sample processing needs.
Sourced in United States, Australia
The Allegra X-12R is a centrifuge designed for general laboratory applications. It features a refrigerated, high-capacity rotor with a maximum speed of 12,100 rpm and a maximum RCF of 21,580 x g. The Allegra X-12R is capable of processing a wide range of sample volumes and tube sizes.
Sourced in United States, Germany, United Kingdom
The Allegra 64R Centrifuge is a high-performance, refrigerated benchtop centrifuge designed for a wide range of laboratory applications. It is capable of reaching a maximum speed of 17,500 rpm and can accommodate various rotor configurations to support different sample volumes and tube sizes.
Sourced in United States
The Allegra X-30R is a refrigerated benchtop centrifuge designed for a variety of laboratory applications. It features a maximum speed of 17,000 RPM and a maximum RCF of 30,110 x g. The Allegra X-30R can accommodate a variety of sample sizes and tube types, making it a versatile centrifuge option for research and clinical laboratories.
Sourced in Germany
The Allegra 3T scanner is a magnetic resonance imaging (MRI) system manufactured by Siemens. It operates at a magnetic field strength of 3 Tesla, providing high-resolution imaging capabilities for medical diagnostic purposes.

More about "Allegra"

Discover the power of Allegra, a third-generation antihistamine medication that provides effective relief for symptoms of allergic rhinitis, including sneezing, itchy and watery eyes, and nasal congestion.
This medication works by blocking the action of histamine, a chemical released by the body during an allergic reaction.
Allegra is available in both prescription and over-the-counter formulations, making it an accessible and well-tolerated treatment option for managing seasonal and year-round allergies.
Beyond its use in treating allergy symptoms, the Allegra name is also associated with various scientific instruments and equipment.
The Allegra X-15R, Allegra 64R, and Allegra X-22R are all centrifuge models designed for efficient separation of samples in a laboratory setting.
The Magnetom Allegra and Allegra 3T scanner are high-performance magnetic resonance imaging (MRI) systems used in medical diagnostic imaging.
These specialized Allegra products demonstrate the versatility and application of the Allegra brand across different fields, from pharmaceutical solutions to advanced scientific instrumentation.
By leveraging the power of AI-driven optimization, tools like PubCompare.ai can help users locate the most reliable and effective Allegra-related protocols, products, and solutions from scientific literature, pre-prints, and patents.
This enables seamless comparisons and ensures users find the best resources to meet their research needs.
Expereince the power of AI-driven optimization and discover the full potential of Allegra today.